To test the potential benefit of piracetam in the treatment of acute ischemic stroke.
- Piracetam (Nootropil®)Drug
Intervention Desc: Mechanism of action unknown; increases cerebral blood flow; inhibits platelet aggregation.
Randomized, double-blind parallel group design trial of 927 patients at 55 centers.
Patients received placebo or 12 g piracetam as an initial intravenous bolus followed by 12 g daily for 4 weeks and then 4.8 g daily for 8 weeks.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Neurologic outcome at 4 weeks as assessed by the Orgogozo scale.|
|Secondary||Functional status at 12 weeks as measured by the Barthel Index.|